AACE/ACE Position statement on the use of follow-on biologics and biosimilars for endocrine diseases

Vivian A. Fonseca, Zachary T. Bloomgarden, Samuel Dagogo-Jack, George Grunberger, Daniel Einhorn, Alan J. Garber, Yehuda Handelsman, Irl B. Hirsch, Guillermo E. Umpierrez

Research output: Contribution to journalArticlepeer-review

4 Scopus citations

Abstract

This document represents the official position of the American Association of Clinical Endocrinologists and American College of Endocrinology. Where there were no randomized controlled trials or specific U.S. FDA labeling for issues in clinical practice, the participating clinical experts utilized their judgment and experience. Every effort was made to achieve consensus among the committee members. Position and consensus statements are meant to provide guidance, but they are not to be considered prescriptive for any individual patient and cannot replace the judgment of a clinician.

Original languageEnglish
Pages (from-to)1345-1349
Number of pages5
JournalEndocrine Practice
Volume23
Issue number11
DOIs
StatePublished - Nov 2017

Fingerprint

Dive into the research topics of 'AACE/ACE Position statement on the use of follow-on biologics and biosimilars for endocrine diseases'. Together they form a unique fingerprint.

Cite this